Approvals: Novartis’ Silver Lining

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-10-01-2001
Volume 0
Issue 0

Basel-A series of product approvals in recent weeks could go some way to compensate for setbacks in Novartis’ pipeline. The approvals came as the Swiss company reported healthy half-year figures and an 11 percent sales increase.

Recent Videos
Fred Aslan
Fred Aslan
Developing Non-Addictive Pain Medication
Related Content